Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) Sees Large Decrease in Short Interest

Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) saw a significant decrease in short interest during the month of February. As of February 15th, there was short interest totalling 91,300 shares, a decrease of 13.6% from the January 31st total of 105,700 shares. Approximately 0.2% of the shares of the stock are sold short. Based on an average daily volume of 142,000 shares, the short-interest ratio is currently 0.6 days.

Institutional Trading of Xtant Medical

An institutional investor recently raised its position in Xtant Medical stock. Geode Capital Management LLC boosted its position in Xtant Medical Holdings, Inc. (NYSEAMERICAN:XTNT) by 70.2% during the 3rd quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 515,006 shares of the medical device company’s stock after acquiring an additional 212,394 shares during the period. Geode Capital Management LLC owned 0.37% of Xtant Medical worth $348,000 at the end of the most recent quarter. Institutional investors and hedge funds own 69.33% of the company’s stock.

Xtant Medical Stock Performance

Shares of XTNT stock opened at $0.50 on Thursday. The business’s fifty day simple moving average is $0.52. The company has a quick ratio of 0.88, a current ratio of 2.12 and a debt-to-equity ratio of 0.42. The company has a market capitalization of $69.49 million, a PE ratio of -3.85 and a beta of 0.35. Xtant Medical has a 52 week low of $0.33 and a 52 week high of $1.24.

Xtant Medical Company Profile

Xtant Medical Holdings, Inc provides regenerative medicine products and medical devices for orthopedic and neurological surgeons. It offers OsteoSponge that provides a natural scaffold for cellular in-growth and exposes bone-forming proteins to the healing environment; OsteoSelect DBM Putty to mold into any shape and compressed into bony voids; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFactor, a processed allograft that contains retained growth factors found within the endosteum layer of allograft bone; OsteoVive Plus, a growth factor enriched cellular bone matrix; and nanOss family of products that provide osteoconductive nano-structured hydroxyapatite and an engineered extracellular matrix bioscaffold collagen carrier.